| scholarly article | Q13442814 |
| P50 | author | Jeong Han Kim | Q37837632 |
| P2093 | author name string | So Young Kwon | |
| Won Hyeok Choe | |||
| Yun Jung Choi | |||
| Soon Young Ko | |||
| Hee Won Moon | |||
| P2860 | cites work | Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. | Q53427565 |
| Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients | Q57782730 | ||
| Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment | Q58235826 | ||
| Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir | Q58376651 | ||
| Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy | Q72087999 | ||
| Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B | Q80188303 | ||
| Editorial: Measurement of HBsAg concentration during antiviral therapy of hepatitis B: who, when, and why | Q85054856 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 | ||
| Evaluation of the patient with hepatitis B | Q33896660 | ||
| KASL Clinical Practice Guidelines: Management of chronic hepatitis B. | Q36153966 | ||
| Type and cause of liver disease in Korea: single-center experience, 2005-2010. | Q36306710 | ||
| Hepatitis B virus resistance to nucleos(t)ide analogues. | Q37593697 | ||
| Current status of liver diseases in Korea: hepatitis B. | Q37663499 | ||
| Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? | Q37969684 | ||
| Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. | Q43136374 | ||
| HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years | Q43895183 | ||
| Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. | Q45385574 | ||
| Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. | Q45398888 | ||
| Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. | Q45889605 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 409-416 | |
| P577 | publication date | 2013-12-28 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data | |
| P478 | volume | 19 |
| Q40272794 | Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. |
| Q34339613 | Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. |
| Q40053947 | Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy |
Search more.